IMMUNE NETWORK

  • 제12권2호
  • /
  • Pages.58-65
  • /
  • 2012
  • /
  • 1598-2629(pISSN)
  • /
  • 2092-6685(eISSN)
대한면역학회 (The Korean Association of Immunobiologists)
권호 표지
DOI QR코드

DOI QR Code

Reactivation of Silenced WT1 Transgene by Hypomethylating Agents - Implications for in vitro Modeling of Chemoimmunotherapy

  • Kwon, Yong-Rim (Laboratory of Hematological Disease and Transplant Immunology, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea) ;
  • Son, Min-Jung (Laboratory of Hematological Disease and Transplant Immunology, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea) ;
  • Kim, Hye-Jung (Laboratory of Hematological Disease and Transplant Immunology, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea) ;
  • Kim, Yoo-Jin (Laboratory of Hematological Disease and Transplant Immunology, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea)
  • 투고 : 2012.03.16
  • 심사 : 2012.04.05
  • 발행 : 2012.04.30
PDF 다운로드
⟨ 이전 논문 다음 논문 ⟩

초록

Background: A cell line with transfected Wilms' tumor protein 1 (WT1) is has been used for the preclinical evaluation of novel treatment strategies of WT1 immunotherapy for leukemia due to the lack of appropriate murine leukemia cell line with endogenous WT1. However, silencing of the transgene occurs. Regarding the effects of hypomethylating agents (HMAs) on reactivation of silenced genes, HMAs are considered to be immune enhancers. Methods: We treated murine WT1- transfected C1498 (mWT1-C1498) with increasing doses of decitabine (DAC) and azacitidine (AZA) to analyze their effects on transgene reactivation. Results: DAC and AZA decreased the number of viable cells in a dose- or time-dependent manner. Quantification of WT1 mRNA level was analyzed by real-time polymerase chain reaction after mWT1-C1498 treated with increasing dose of HMA. DAC treatment for 48 h induced 1.4-, 14.6-, and 15.5-fold increment of WT1 mRNA level, compared to untreated sample, at 0.1, 1, and $10{\mu}M$, respectively. Further increment of WT1 expression in the presence of 1 and $10{\mu}M$ DAC was evident at 72 h. AZA treatment also induced up-regulation of mRNA, but not to the same degree as with DAC treatment. The correlation between the incremental increases in WT1 mRNA by DAC was confirmed by Western blot and concomitant down-regulation of WT1 promoter methylation was revealed. Conclusion: The in vitro data show that HMA can induce reactivation of WT1 transgene and that DAC is more effective, at least in mWT1-C1498 cells, which suggests that the combination of DAC and mWT1-C1498 can be used for the development of the experimental model of HMA-combined WT1 immunotherapy targeting leukemia.

키워드

참고문헌

  1. Roddie C, Peggs KS: Donor lymphocyte infusion following allogeneic hematopoietic stem cell transplantation. Expert Opin Biol Ther 11;473-487, 2011. https://doi.org/10.1517/14712598.2011.554811
  2. Cheever MA, Allison JP, Ferris AS, Finn OJ, Hastings BM, Hecht TT, Mellman I, Prindiville SA, Viner JL, Weiner LM, Matrisian LM: The prioritization of cancer antigens: a national cancer institute pilot project for the acceleration of translational research. Clin Cancer Res 15;5323-5337, 2009. https://doi.org/10.1158/1078-0432.CCR-09-0737
  3. Sugiyama H: WT1 (Wilms tumor gene 1): biology and cancer immunotherapy. Jpn J Clin Oncol 40;377-387, 2010. https://doi.org/10.1093/jjco/hyp194
  4. Menssen HD, Renkl HJ, Rodeck U, Kari C, Schwartz S, Thiel E: Detection by monoclonal antibodies of the Wilms tumor (WT1) nuclear protein in patients with acute leukemia. Int J Cancer 70;518-523, 1997. https://doi.org/10.1002/(SICI)1097-0215(19970304)70:5<518::AID-IJC5>3.0.CO;2-0
  5. Baird PN, Simmons PJ: Expression of the Wilms tumor gene (WT1) in normal hemopoiesis. Exp Hematol 25;312-320,1997.
  6. Yamagami T, Sugiyama H, Inoue K, Ogawa H, Tatekawa T, Hirata M, Kudoh T, Akiyama T, Murakami A, Maekawa T: Growth inhibition of human leukemic cells by WT1 (Wilms tumor gene) antisense oligodeoxynucleotides: implications for the involvement of WT1 in leukemogenesis. Blood 87; 2878-2884, 1996.
  7. Scheibenbogen C, Letsch A, Thiel E, Schmittel A, Mailaender V, Baerwolf S, Nagorsen D, Keilholz U: CD8 T-cell responses to Wilms tumor gene product WT1 and proteinase 3 in patients with acute myeloid leukemia. Blood 100;2132-2137,2002. https://doi.org/10.1182/blood-2002-01-0163
  8. Rezvani K, Brenchley JM, Price DA, Kilical Y, Gostick E, Sewell AK, Li J, Mielke S, Douek DC, Barrett AJ: T-cell responses directed against multiple HLA-A*0201-restricted epitopes derived from Wilms' tumor 1 protein in patients with leukemia and healthy donors: identification, quantification, and characterization. Clin Cancer Res 11;8799-8807, 2005. https://doi.org/10.1158/1078-0432.CCR-05-1314
  9. Ohminami H, Yasukawa M, Fujita S: HLA class I-restricted lysis of leukemia cells by a CD8(＋) cytotoxic T-lymphocyte clone specific for WT1 peptide. Blood 95;286-293, 2000.
  10. Mailänder V, Scheibenbogen C, Thiel E, Letsch A, Blau IW, Keilholz U: Complete remission in a patient with recurrent acute myeloid leukemia induced by vaccination with WT1 peptide in the absence of hematological or renal toxicity. Leukemia 18;165-166, 2004. https://doi.org/10.1038/sj.leu.2403186
  11. Rezvani K, Yong AS, Mielke S, Savani BN, Musse L, Superata J, Jafarpour B, Boss C, Barrett AJ: Leukemia-associated antigen- specific T-cell responses following combined PR1 and WT1 peptide vaccination in patients with myeloid malignancies. Blood 111;236-242, 2007.
  12. Van Tendeloo VF, Van de Velde A, Van Driessche A, Cools N, Anguille S, Ladell K, Gostick E, Vermeulen K, Pieters K, Nijs G, Stein B, Smits EL, Schroyens WA, Gadisseur AP, Vrelust I, Jorens PG, Goossens H, de Vries IJ, Price DA, Oji Y, Oka Y, Sugiyama H, Berneman ZN: Induction of complete and molecular remissions in acute myeloid leukemia by Wilms􀙗 tumor 1 antigen-targeted dendritic cell vaccination. Proc Natl Acad Sci U S A 107;13824-13829, 2010. https://doi.org/10.1073/pnas.1008051107
  13. Keilholz U, Letsch A, Busse A, Asemissen AM, Bauer S, Blau IW, Hofmann WK, Uharek L, Thiel E, Scheibenbogen C: A clinical and immunologic phase 2 trial of Wilms tumor gene product 1 (WT1) peptide vaccination in patients with AML and MDS. Blood 113;6541-6548, 2009. https://doi.org/10.1182/blood-2009-02-202598
  14. Kim YJ, Cho SG, Lee S, Kim MS, Kim EK, Cho BS, Sohn HJ, Choi HB, Eom KS, Min CK, Kim HJ, Kim YG, Kim DW, Lee JW, Min WS, Kim CC, Kim TG: Potential role of adoptively transferred allogeneic WT1-specific CD4+ and CD8+ T lymphocytes for the sustained remission of refractory AML. Bone Marrow Transplant 45;597-599, 2010. https://doi.org/10.1038/bmt.2009.191
  15. Van Driessche A, Berneman ZN, Van Tendeloo VF: Active specific immunotherapy targeting the Wilms􀙗 tumor protein 1 (WT1) for patients with hematological malignancies and solid tumors: lessons from early clinical trials. Oncologist 17;250-259, 2012. https://doi.org/10.1634/theoncologist.2011-0240
  16. Buckler AJ, Pelletier J, Haber DA, Glaser T, Housman DE: Isolation, characterization, and expression of the murine Wilms􀙗 tumor gene (WT1) during kidney development. Mol Cell Biol 11;1707-1712, 1991. https://doi.org/10.1128/MCB.11.3.1707
  17. Fraizer GC, Patmasiriwat P, Zhang X, Saunders GF: Expression of the tumor suppressor gene WT1 in both human and mouse bone marrow. Blood 86;4704-4706, 1995.
  18. Oka Y, Udaka K, Tsuboi A, Elisseeva OA, Ogawa H, Aozasa K, Kishimoto T, Sugiyama H: Cancer immunotherapy targeting Wilms􀙗 tumor gene WT1 product. J Immunol 164;1873-1880, 2000. https://doi.org/10.4049/jimmunol.164.4.1873
  19. Houdebine LM: Transgenic animal bioreactors. Transgenic Res 9;305-320, 2000. https://doi.org/10.1023/A:1008934912555
  20. Migliaccio AR, Bengra C, Ling J, Pi W, Li C, Zeng S, Keskintepe M, Whitney B, Sanchez M, Migliaccio G, Tuan D: Stable and unstable transgene integration sites in the human genome: extinction of the Green Fluorescent Protein transgene in K562 cells. Gene 256;197-214, 2000. https://doi.org/10.1016/S0378-1119(00)00353-X
  21. Cedar H: DNA methylation and gene activity. Cell 53;3-4,1988. https://doi.org/10.1016/0092-8674(88)90479-5
  22. Challita PM, Kohn DB: Lack of expression from a retroviral vector after transduction of murine hematopoietic stem cells is associated with methylation in vivo. Proc Natl Acad Sci U S A 91;2567-2571, 1994. https://doi.org/10.1073/pnas.91.7.2567
  23. Hoeben RC, Migchielsen AA, van der Jagt RC, van Ormondt H, van der Eb AJ: Inactivation of the Moloney murine leukemia virus long terminal repeat in murine fibroblast cell lines is associated with methylation and dependent on its chromosomal position. J Virol 65;904-912, 1991.
  24. Jaenisch R, Schnieke A, Harbers K: Treatment of mice with 5-azacytidine efficiently activates silent retroviral genomes in different tissues. Proc Natl Acad Sci U S A 82;1451-1455, 1985. https://doi.org/10.1073/pnas.82.5.1451
  25. Rosenfeld C, Cheever MA, Gaiger A: WT1 in acute leukemia, chronic myelogenous leukemia and myelodysplastic syndrome: therapeutic potential of WT1 targeted therapies. Leukemia 17;1301-1312, 2003. https://doi.org/10.1038/sj.leu.2402988
  26. Lake RA, Robinson BW: Immunotherapy and chemotherapy-- a practical partnership. Nat Rev Cancer 5;397-405, 2005. https://doi.org/10.1038/nrc1613
  27. Kim HS, Park HM, Park JS, Sohn HJ, Kim SG, Kim HJ, Oh ST, Kim TG: Dendritic cell vaccine in addition to FOLFIRI regimen improve antitumor effects through the inhibition of immunosuppressive cells in murine colorectal cancer model. Vaccine 28;7787-7796, 2010. https://doi.org/10.1016/j.vaccine.2010.09.046
  28. Parikh SA, Keating MJ, O'Brien S, Wang X, Ferrajoli A, Faderl S, Burger J, Koller C, Estrov Z, Badoux X, Lerner S, Wierda WG: Frontline chemoimmunotherapy with fludarabine, cyclophosphamide, alemtuzumab, and rituximab for high-risk chronic lymphocytic leukemia. Blood 118;2062-2068, 2011. https://doi.org/10.1182/blood-2011-01-329177
  29. Guo ZS, Hong JA, Irvine KR, Chen GA, Spiess PJ, Liu Y, Zeng G, Wunderlich JR, Nguyen DM, Restifo NP, Schrump DS: De novo induction of a cancer/testis antigen by 5-aza-2'-deoxycytidine augments adoptive immunotherapy in a murine tumor model. Cancer Res 66;1105-1113, 2006. https://doi.org/10.1158/0008-5472.CAN-05-3020
  30. Fonsatti E, Nicolay HJ, Sigalotti L, Calabrò L, Pezzani L, Colizzi F, Altomonte M, Guidoboni M, Marincola FM, Maio M: Functional up-regulation of human leukocyte antigen class I antigens expression by 5-aza-2'-deoxycytidine in cutaneous melanoma: immunotherapeutic implications. Clin Cancer Res 13;3333-3338, 2007. https://doi.org/10.1158/1078-0432.CCR-06-3091
  31. Sigalotti L, Altomonte M, Colizzi F, Degan M, Rupolo M, Zagonel V, Pinto A, Gattei V, Maio M: 5-Aza-2'-deoxycytidine (decitabine) treatment of hematopoietic malignancies: a multimechanism therapeutic approach? Blood 101;4644-4646,2003. https://doi.org/10.1182/blood-2002-11-3458
  32. Choi J, Ritchey J, Prior JL, Holt M, Shannon WD, Deych E, Piwnica-Worms DR, DiPersio JF: In vivo administration of hypomethylating agents mitigate graft-versus-host disease without sacrificing graft-versus-leukemia. Blood 116;129-139,2010. https://doi.org/10.1182/blood-2009-12-257253
  33. Goodyear O, Agathanggelou A, Novitzky-Basso I, Siddique S, McSkeane T, Ryan G, Vyas P, Cavenagh J, Stankovic T, Moss P, Craddock C: Induction of a CD8+ T-cell response to the MAGE cancer testis antigen by combined treatment with azacitidine and sodium valproate in patients with acute myeloid leukemia and myelodysplasia. Blood 116;1908-1918, 2010. https://doi.org/10.1182/blood-2009-11-249474
  34. Gaiger A, Reese V, Disis ML, Cheever MA: Immunity to WT1 in the animal model and in patients with acute myeloid leukemia. Blood 96;1480-1489, 2000.
  35. Hollenbach PW, Nguyen AN, Brady H, Williams M, Ning Y, Richard N, Krushel L, Aukerman SL, Heise C, MacBeth KJ: A comparison of azacitidine and decitabine activities in acute myeloid leukemia cell lines. PLoS One 5;1-10, 2010.
  36. Grassi G, Maccaroni P, Meyer R, Kaiser H, D'Ambrosio E, Pascale E, Grassi M, Kuhn A, Di Nardo P, Kandolf R, Küpper JH: Inhibitors of DNA methylation and histone deacetylation activate cytomegalovirus promoter-controlled reporter gene expression in human glioblastoma cell line U87. Carcinogenesis 24;1625-1635, 2003. https://doi.org/10.1093/carcin/bgg118
  37. Swindle CS, Klug CA: Mechanisms that regulate silencing of gene expression from retroviral vectors. J Hematother Stem Cell Res 11;449-456, 2002. https://doi.org/10.1089/15258160260090915

피인용 문헌

  1. Dendritic Cells as Pharmacological Tools for Cancer Immunotherapy vol.67, pp.4, 2012, https://doi.org/10.1124/pr.114.009456
  2. Consolidation therapy with decitabine and intermediate-dose cytarabine followed by HLA-mismatched peripheral blood stem cells infusion for older patients with acute myeloid leukemia in first remission vol.59, pp.7, 2012, https://doi.org/10.1080/10428194.2017.1390235
  3. 地西他滨联合微移植巩固治疗首次完全缓解老年急性髓系白血病的疗效与安全性分析 vol.39, pp.4, 2018, https://doi.org/10.3760/cma.j.issn.0253-2727.2018.04.010